Chrono Therapeutics, developer of a digital drug delivery system, has raised $47.6m in a Kaiser Permanente-led round that included several other corporates.

Vivasure Medical has closed an $18.3m series C round co-led by Evonik Venture Capital and will use the cash to commercialise its blood vessel closure device.

The round, which includes $140m from AstraZeneca, was announced alongside a Zika vaccine-related US government grant that could reach $125m in size.

Santen Pharmaceutical and Nerveda RetroSense have exited eye disease treatment developer RetroSense, which had raised about $12m in funding.

Allergan has acquired the Wayne State University spinout, backed by Santen Pharmaceutical and Nerveda, for an upfront payment of $60m with potential milestone payments in future.

Boehringer Ingelheim was among the investors as the RNA therapeutics developer reached the final close of a round it began raising in 2014.

The Cambridge spinout has secured cash from the Cambridge Enterprise Seed Fund, Cambridge Innovation Capital, Parkwalk Advisors and others.

The chipmaker's corporate venturing arm, Applied Ventures, is putting together a team in Singapore to increase its activities in Asia.